Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more
Cantargia AB (CANTA) - Total Liabilities
Latest total liabilities as of September 2025: Skr61.31 Million SEK
Based on the latest financial reports, Cantargia AB (CANTA) has total liabilities worth Skr61.31 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cantargia AB - Total Liabilities Trend (2011–2024)
This chart illustrates how Cantargia AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cantargia AB Competitors by Total Liabilities
The table below lists competitors of Cantargia AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AME Elite Consortium Bhd
KLSE:5293
|
Malaysia | RM1.02 Billion |
|
Hanla IMS Co. Ltd
KQ:092460
|
Korea | ₩37.29 Billion |
|
IGM Biosciences Inc
NASDAQ:IGMS
|
USA | $6.06 Million |
|
Kish Bancorp Inc
OTCQX:KISB
|
USA | $1.72 Billion |
|
K-Fast Holding AB (publ)
ST:KFAST-B
|
Sweden | Skr19.09 Billion |
|
Musti Group Oyj
HE:MUSTI
|
Finland | €288.33 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Cantargia AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cantargia AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cantargia AB (2011–2024)
The table below shows the annual total liabilities of Cantargia AB from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr54.12 Million | -1.54% |
| 2023-12-31 | Skr54.97 Million | -35.42% |
| 2022-12-31 | Skr85.11 Million | +26.10% |
| 2021-12-31 | Skr67.50 Million | +101.02% |
| 2020-12-31 | Skr33.58 Million | +41.18% |
| 2019-12-31 | Skr23.78 Million | +45.04% |
| 2018-12-31 | Skr16.40 Million | -42.12% |
| 2017-12-31 | Skr28.33 Million | +172.85% |
| 2016-12-31 | Skr10.38 Million | +212.02% |
| 2015-12-31 | Skr3.33 Million | -79.24% |
| 2014-12-31 | Skr16.03 Million | +1768.34% |
| 2013-12-31 | Skr858.07K | +23.05% |
| 2012-12-31 | Skr697.32K | -19.04% |
| 2011-12-31 | Skr861.27K | -- |